Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Short term Debt (2016 - 2023)

Amicus Therapeutics' Short term Debt history spans 13 years, with the latest figure at $13.0 million for Q2 2023.

  • For the quarter ending Q2 2023, Short term Debt fell 32.5% year-over-year to $13.0 million, compared with a TTM value of $13.0 million through Jun 2023, down 32.5%, and an annual FY2022 reading of $21.4 million, up 13.32% over the prior year.
  • Short term Debt for Q2 2023 was $13.0 million at Amicus Therapeutics, up from $12.7 million in the prior quarter.
  • The five-year high for Short term Debt was $21.4 million in Q4 2022, with the low at $8.9 million in Q4 2020.
  • Average Short term Debt over 4 years is $17.2 million, with a median of $19.2 million recorded in 2022.
  • Year-over-year, Short term Debt skyrocketed 112.36% in 2021 and then crashed 33.85% in 2023.
  • Tracing FOLD's Short term Debt over 4 years: stood at $8.9 million in 2020, then skyrocketed by 112.36% to $18.9 million in 2021, then rose by 13.32% to $21.4 million in 2022, then tumbled by 39.28% to $13.0 million in 2023.
  • Per Business Quant, the three most recent readings for FOLD's Short term Debt are $13.0 million (Q2 2023), $12.7 million (Q1 2023), and $21.4 million (Q4 2022).